Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
3.140
-0.170 (-5.14%)
At close: Mar 9, 2026, 4:00 PM EDT
3.080
-0.060 (-1.91%)
After-hours: Mar 9, 2026, 4:03 PM EDT
Acumen Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
192.02M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arcturus Therapeutics Holdings | 82.03M |
| Compugen | 72.76M |
| Protalix BioTherapeutics | 61.84M |
| Editas Medicine | 46.38M |
| Cibus | 3.79M |
| Humacyte | 1.57M |
| NeOnc Technologies Holdings | 59.99K |
ABOS News
- 4 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 6 months ago - Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 7 months ago - Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewsWire
- 8 months ago - JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform - Business Wire
- 8 months ago - Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025 - GlobeNewsWire